Poison the tumor,
spare the patient

Precision chemotherapy™

Pharma in silica engineers a game-changer for millions of cancer patients: a treatment that improves outcomes and reduces harm

Problem: chemotherapy

A major & overlooked medical need

Current chemo often brings limited improvements in survival and remission, in part because it disrupts the immune system, inhibiting the patient’s natural ability to neutralize cancer cells. Chemotherapy also imposes painful, long-lasting, and costly side effects (anemia, infections, neurological disorders, discomfort, etc.).

Cytotoxic drugs are nevertheless routinely used alongside surgery, radiation, immunotherapy, hormone therapy, and cell-based treatments, generating over $18B in annual sales. Shockingly chemotherapy remains one of the most under-studied treatments in oncology: few clinical trials focus on the safety and effectiveness of these treatments, exposing patients to regressive therapeutic methods.

Solution: add precision to chemo

Our mission: to kill tumor cells without maiming the person living with the cancer

A universal, precise & well-tolerated treatment

Universal Precision Well-tolerated treatment
Pharma in silica’s scientists are developing a proprietary silica nanocarrier that circulates extensively in the blood without affecting the biological activity of blood cells and delivers large quantities of cytotoxic agents specifically to the tumor. This unprecedented precision is expected to increase treatment efficacy and significantly reduce side effects.

Technology: a silica-made nanoparticule

that promotes innocuity & efficacity of cytotoxic drugs

Silica nanocarrier

(high-resolution scanning electron microscopy)
Tumeur
Silica matrix
Entrapper drug
Surface coating
Anchoring sites
  • Biocompatible
  • FDA-accepted
  • Versatile chemistry
  • Cytotoxic drug safely stored in large pores
  • Release triggered by tumor environment
  • For stability & stealth in blood
  • For radiotherapy, targeted delivery, diagnostic, etc.

Roadmap: 10M + 30 months = 2B exit

2026 2027 2028 2029
Pre-clinical
Clinical
Commercial
Industrial
2. Nano-oncology platform

Novel prototypes

Licenses to cutting-edge onco pharmas

3. Inflection point

Exit opportunities
± US$ 2B value

4. DMO

Development &
manufacture org.
(business unit
or company)

1. Beachhead product OpPacli/NSCLC

Regulatory studies 505(b)(2)

Phase Ib/IIa

Licenses to the Kings of chemo

A factory of product-candidates

Pharma in silica‘s intends to leverage its mastery of silica chemistry and early-stage product development to partner with pharmas, like the swiss Debiopharm does with organic chemistry & the Vancouver-based abCellera with bivalent antibodies. The first partnerships, licenses at technical and human proof-of-concept stages, will eventually become longer-term co-development endeavors.

2026 - Pre-clinical

1. Beachhead product OpPacli/NSCLC

Regulatory studies 505(b)(2)

2. Nano-oncology platform

Novel prototypes

2027 - Clinical

1. Beachhead product OpPacli/NSCLC

Phase Ib/IIa

2028 - Commercial

1. Beachhead product OpPacli/NSCLC

Licenses to the Kings of chemo

A factory of product-candidates

Pharma in silica‘s intends to leverage its mastery of silica chemistry and early-stage product development to partner with pharmas, like the swiss Debiopharm does with organic chemistry & the Vancouver-based abCellera with bivalent antibodies. The first partnerships, licenses at technical and human proof-of-concept stages, will eventually become longer-term co-development endeavors.

2. Nano-oncology platform

Licenses to cutting-edge onco pharmas

3. Inflection point

Exit opportunities
± US$ 2B value

2029 - Industrial

4. DMO

Development &
manufacture org.
(business unit
or company)

Team & corporate info

An agile group of experts in material science, early-stage product development & deal making led by seasoned managers

François Arcand, MBA

President & cofounder

François Arcand, MBA

Co-founder of Medicago (Quebec), CEO of ERA Biotech (Barcelona)

Myriam Laprise-Pelletier, PhD

Chief technology officer

Myriam Laprise-Pelletier, PhD

Nanomaterial science for biomedical applications & imaging at Université Laval (Québec)

Mahmoud Omar, PhD

Translational science

Mahmoud Omar, PhD

PK/PD & nanomaterial science for biomedical applications at Université Laval (Québec)

Jean-François Haince, PhD

Business development

Jean-François Haince, PhD

Oncology R&D/business dev. & tech transfer

(Q4 2026)

Medical director

(Q4 2026)

Oncologist expert in chemo & early-stage drug development

Consultant & advisors

Regulatory, product dev., CMC & process dev., intellectual property, tax credits, reimbursements, law & accounting

Laboratories Pharma in silica inc.

Canadian private corporation (provincial charter)
Shareholders: accredited investors, Investment Québec,
cofounders (no controlling shareholder)

Contact

Mr François Arcand MBA, President
arcandf@pharma-insilica.com
2500 boul. du Parc-Technologies, Quebec, Qc Canada G1P 4S6

Financial info

Toward first IND, novel platform & pharma partnerships

Pharma in silica launched in Q2 2026 a multi-tranche US$ 10M seed round to, in 30 ~ 36 months:

  • obtain IND/CTA for its first product;
  • complete a phase Ib/IIa human study with OpPacli vs non small-cell lung carcinoma (NSCLC);
  • develop 3 novel prototypes (in vivo proof of concept and business case);
  • execute a 1st pharma deal (upfront US$ 28 to 58 M USD, overall value 450M);
  • generate a pipeline of additional deals;
  • reach cash positiveness;
  • provide its shareholders with multiple exit opportunities at a valuation of ± US$ 2B.

Corporate, technical & financial information are available upon request. Laboratories Pharma in silica inc. is audited by EY as per the international financial reporting standards.

Image